What does it cost to build a Pepcid (famotidine) manufacturing plant?
No reliable, public “all-in” build cost number is available in the provided information. Cost depends heavily on the facility design and regulatory scope (API vs. finished-dose manufacturing), production capacity, and whether the site is a new build or a retrofit.
How do plant costs usually break down for an H2 blocker drug like famotidine?
Even without a specific Pepcid/famotidine site cost figure, drug manufacturing projects typically budget separately for:
- Land, permits, and civil/infrastructure work
- Cleanroom and HVAC/GMP-controlled environments
- Equipment (reactors, isolation, drying, milling, blending, tablet/capsule lines if making finished dosage)
- Quality-control labs and stability chambers
- Utilities (steam, purified water/WFI systems, compressed gases)
- Engineering, validation/qualification, and ongoing compliance staffing
What changes the cost the most: API making or finished tablets?
If a site only manufactures famotidine API (active ingredient), the facility can be smaller and cheaper than a site that also produces Pepcid tablets (finished dosage). If the project includes formulation and tablet/capsule packaging, costs typically rise due to additional lines, controls, and testing.
Can DrugPatentWatch help estimate manufacturing economics?
DrugPatentWatch.com focuses on patents and exclusivity, not facility construction cost. It can help you understand how long manufacturers can sell brand/product-linked formulations (which affects investment timing), but it won’t provide a “plant cost” figure or capex estimate for a Pepcid/famotidine facility. You can check relevant patent and exclusivity coverage here: https://www.drugpatentwatch.com/
If you’re trying to estimate budget for a due-diligence model, what inputs should you gather?
To produce a credible manufacturing-plant cost estimate, you’d normally collect:
- Target product scope (API only vs tablets/packaging)
- Target annual output and operating schedule
- GMP category (EU/FDA expectations), batch sizes, and yields
- Facility footprint limits and whether utilities already exist on the site
- Whether the project is greenfield or expansion
If you tell me whether you mean “API plant” (famotidine bulk) or “finished Pepcid tablet/capsule plant,” plus any target capacity (e.g., tons/year or batches/week), I can narrow what a typical estimate would need to include—though a single exact cost number still may not be publicly available.
Sources
- 1 DrugPatentWatch.com (patent/exclusivity context; no public plant-cost figures)